Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HLN
STRONG BUYFLAGHaleon plc · Healthcare · United Kingdom · $43.1B · Avg Vol: $92M/d
Haleon has quality Q65 and momentum M64, but value at V56 misses the all-three-above-60 path with no corroborating filing, so stage one fails.
COMPANY DESCRIPTION
Haleon plc is the world's largest pure-play consumer healthcare company, boasting a portfolio of category-leading brands such as Sensodyne, Advil, and Centrum. Spun off from GSK and Pfizer, the company possesses a powerful competitive moat built on deep clinical heritage, strong brand equity, and extensive global retail distribution. It operates as a highly defensive, cash-generative business well-positioned to benefit from secular trends in self-care and aging demographics.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 14.3B | 14.9B | 14.8B | 14.6B | 0.5% | 14.6B | 15.0B | 15.7B | 3.8% |
| EPS | — | 0.64 | 0.63 | 0.86 | 0.99 | 16.0% | 0.49 | 1.07 | 1.19 | 9.3% |
| Shares | — | 4.4B | 4.4B | 4.4B | 4.4B | 0.0% | 4.4B | — | — | — |
| Debt | — | 13.8B | 12.4B | 13.3B | 11.3B | -6.3% | 11.4B | — | — | — |
| Equity | — | 21.6B | 21.9B | 21.3B | 21.7B | 0.2% | — | — | — | — |
| Op CF | 1.8B | 2.7B | 2.8B | 3.0B | 3.5B | 18.1% | 3.5B | — | — | — |
| Inv CF | -43.6M | -11.6B | -176.9M | 696.9M | -456.7M | — | — | — | — | — |
| Fin CF | -1.6B | 9.1B | -2.1B | -2.0B | -4.1B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HLN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HLN | Haleon plc(you) | $43.1B | 86 | STRONG BUY |
| KNSA | Kiniksa Pharmaceuticals International, plc | $4.8B | 87 | STRONG BUY |
| HIK.L | Hikma Pharmaceuticals PLC | $4.3B | 89 | STRONG BUY |
| ANCR.L | Animalcare Group plc | $302M | 90 | STRONG BUY |
| SN.L | Smith & Nephew plc | $12.7B | 85 | STRONG BUY |
| GSK | GSK plc | $102.8B | 96 | STRONG BUY |
| EAH.L | ECO Animal Health Group plc | $78M | 92 | STRONG BUY |
| AZN | AstraZeneca PLC | $262.5B | 83 | STRONG BUY |
| LIVN | LivaNova PLC | $4.3B | 79 | BUY |
| CTEC.L | Convatec Group PLC | $5.5B | 64 | HOLD |
Peer medians: ROE -3.8% · P/E 25.2x · Gross margin 53.3%